The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed the reviewed and updated rheumatoid arthritis pathways (moderate and severe).

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends filogtinib as a treatment option for the treatment of moderate to severe Rheumatoid Arthritis in line with NICE TA676

Filgotinib will be considered RED on the traffic light system. Prescribing will be by hospital specialists only, in line with NICE TA676.

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

The current Rheumatoid Arthritis high cost DMARDs treatment pathway is attached below and will be updated by the Rheumatology Clinical Network members in due course.